N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis

Completed · Phase 2 · Has a placebo group

Conditions studied: Schizophrenic Psychoses

In brief

The investigators seek to examine the effect of add-on N-Acetyl-Cysteine (NAC) in the early phase of schizophrenia spectrum illness in collaboration with researchers Kim Do, PhD, and Philippe Conus, MD in Switzerland. Modifications of brain structure are thought to occur during the pre-illness phase and around the transition to psychosis. Therefore, studying new treatments that could target changes occurring during this period is of critical importance. Aims: Does add-on NAC treatment in early psychosis influence: * positive and negative symptoms * extrapyramidal side-effects of other medication * plasma concentration of glutathione * Mismatch Negativity, a physiological marker

Key facts

Study ID
NCT01354132
Run by
Beth Israel Deaconess Medical Center
People needed
20
Starts
2011-05-01
Expected to finish
2014-08-01
Last updated by the study team
2017-07-05

Who can join

Age: 18 and older, up to 35. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.